文献速递临床试验与 GCP

通过调节镁和磷酸盐逆转动脉疾病(ROADMAP研究):评估柠檬酸镁补充与磷酸盐结合治疗对中度慢性肾脏病动脉僵硬度影响的随机对照试验原理与设计

Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
PubMed 文献 · Trials · 2022-09-12

ROADMAP是一项多中心、安慰剂对照随机对照试验,计划纳入180例估算肾小球滤过率15至50 ml/min/1.73 m2且未使用磷酸盐结合剂的3-4期慢性肾脏病患者。参与者随机接受柠檬酸镁(元素镁350 mg/天)或安慰剂,联合或不联合磷酸盐结合剂蔗糖氢氧化氧铁(1000 mg/天),干预24周。主要结局为颈-股脉搏波速度测量的动脉僵硬度变化。

要点

  • 3-4期慢性肾脏病患者中,镁与磷酸盐是血管钙化和慢性炎症的调节因素。
  • 试验采用2×2析因设计,比较柠檬酸镁与安慰剂,联合或不联合蔗糖氢氧化氧铁。
  • 主要结局为24周颈-股脉搏波速度变化,次要结局包括钙化倾向(T50)和高敏C反应蛋白。

核心结论

  • 联合补充柠檬酸镁与蔗糖氢氧化氧铁降低磷酸盐治疗旨在调节导致血管钙化和动脉僵硬的矿物质代谢紊乱,并确定该效应在多大程度上由T50变化介导。
  • 研究结果可能有助于未来慢性肾脏病患者的早期干预,以降低心血管疾病和死亡风险。

研究设计与样本

  • 多中心、安慰剂对照随机对照试验,计划纳入180例估算肾小球滤过率为15至50 ml/min/1.73 m2且未接受磷酸盐结合剂治疗的参与者。
  • 干预24周,参与者随机分入四组之一:柠檬酸镁(元素镁350 mg/天)或安慰剂,联合或不联合磷酸盐结合剂蔗糖氢氧化氧铁(1000 mg/天)。
  • 在基线、12周和24周测量主要和次要终点;在40例参与者子集中重复进行18F-FDG和18F-NaF PET扫描作为探索性终点。

主要发现

  • 主要结局为24周颈-股脉搏波速度测量的动脉僵硬度变化。
  • 次要结局包括钙化标志物和炎症标志物,其中包括钙化倾向(T50)和高敏C反应蛋白。
  • 探索性终点为在40例参与者子集中重复进行18F-FDG和18F-NaF PET扫描。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arterial stiffness and calcification propensity are associated with high cardiovascular risk and increased mortality in chronic kidney disease (CKD). Both magnesium and phosphate are recognized as modulators of vascular calcification and chronic inflammation, both features of CKD that contribute to arterial stiffness. In this paper, we outline the rationale and design of a randomized controlled trial (RCT) investigating whether 24 weeks of oral magnesium supplementation with or without additional phosphate-binding therapy can improve arterial stiffness and calcification propensity in patients with stage 3-4 CKD. METHODS: In this multi-center, placebo-controlled RCT, a total of 180 participants with an estimated glomerular filtration rate of 15 to 50 ml/min/1.73 m2 without phosphate binder therapy will be recruited. During the 24 weeks intervention, participants will be randomized to one of four intervention groups to receive either magnesium citrate (350 mg elemental magnesium/day) or placebo, with or without the addition of the phosphate binder sucroferric oxyhydroxide (1000 mg/day). Primary outcome of the study is the change of arterial stiffness measured by the carotid-femoral pulse wave velocity over 24 weeks. Secondary outcomes include markers of calcification and inflammation, among others calcification propensity (T50) and high-sensitivity C-reactive protein. As explorative endpoints, repeated 18F-FDG and 18F-NaF PET-scans will be performed in a subset of participants (n = 40). Measurements of primary and secondary endpoints are performed at baseline, 12 and 24 weeks. DISCUSSION: The combined intervention of magnesium citrate supplementation and phosphate-lowering therapy with sucroferric oxyhydroxide, in stage 3-4 CKD patients without overt hyperphosphatemia, aims to modulate the complex and deregulated mineral metabolism leading to vascular calcification and arterial stiffness and to establish to what extent this is mediated by T50 changes. The results of this combined intervention may contribute to future early interventions for CKD patients to reduce the risk of CVD and mortality. TRIAL REGISTRATION: Netherlands Trial Register, NL8252 (registered December 2019), EU clinical Trial Register 2019-001306-23 (registered November 2019).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Vermeulen EA, Eelderink C, Hoekstra T, et al. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease. Trials. 2022. PMID: 36096824. doi:10.1186/s13063-022-06562-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。